e/ -- Micell Technologies, Inc . announced completion of enrollment in the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT) study. The study will compare changes in coronary arteries between six and 24 months following treatment with MiStent or XIENCE V Everolimus Eluting Coronary Stent System (Xience). The clinical investigation and data analysis are being conducted by Cardialysis and the European Cardiovascular Research Institute (ECRI), in Rotterdam, The Netherlands. The OCT study will evaluate 60 patients randomized to MiStent or Xience. A prior MiStent clinical study has shown essentially no increase in late lumen loss between ...

Frost & Sullivan honored recipients of its 2016 Excellence in Best Practices Awards at a gala held Wednesday, January 13, in San Diego, Calif., at the Hilton San Diego Resort & Spa. With a festive ambiance and exciting Awards, the event brought together top executives to celebrate their success. The Awards gala was preceded by a 90-minute Frost & Sullivan Demand & Brand Workshop, designed exclusively for company leaders seeking to grow their brand recognition... Bioptigen, Inc. – 2015 North American Ophthalmic Imaging Technology Leadership Award

MedLumics , a cardiology device company specializing in the application of advanced optical coherence tomography (OCT) technology, has announced the appointment of cardiovascular device veteran Tim Lenihan to its board of directors. With vast experience in field of electrophysiology, Lenihan will help guide the continued advancement of the company’s catheter ablation technology for the treatment of atrial fibrillation. “We are very fortunate to add Tim to our board of directors given his domain expertise in catheter-based medical technologies, specifically in the cardiac ablation field,” said Eduardo Margallo, CEO of MedLumics. “His experience and insights will undoubtedly make an enormous contribution ...

Optovue, the global leader in the clinical development and commercialization of optical coherence tomography angiography (OCTA), today announced that it will showcase several advanced technologies at AAO 2015, the 119 th annual meeting of the American Academy of Ophthalmology, being held in Las Vegas from November 14-17. Total Cornea Power (TCP™) and the AngioVue™* Imaging System with AngioAnalytics™*, are designed to improve disease and procedure management, which may lead to improved outcomes for patients with sight-threatening diseases

The medical devices industry, which was once acclaimed for its high-paying jobs and research and development opportunities, has been subject to the much controversial 2.3% medical device excise tax since its enactment in the beginning of 2013. Sequestration-related spending cuts to the U.S. federal budget have also undermined the medical devices industry’s prospects. In fact, this has significantly restricted the industry’s bottom-line improvement in the past year.